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In the past 20 years great progress has been made in the
development of multidimensional outcome measures
(such as the Disease Activity Score and ACR20) to
evaluate treatments in rheumatoid arthritis, a process
disseminated throughout rheumatic diseases. These
outcome measures have standardized the assessment of
outcomes in trials, making it possible to evaluate and
compare the efficacy of treatments. The methodologic
advances have included the selection of pre-existing
outcome measures that detected change in a sensitive
fashion (in rheumatoid arthritis, this was the Core Set
Measures). These measures were then combined into a
single multidimensional outcome measure and such
outcome measures have been widely adopted in trials
and endorsed by the American College of Rheumatology
(ACR) and the European League Against Rheumatism
(EULAR) and regulatory agencies. The secular
improvement in treatment for patients with rheumatoid
arthritis has been facilitated in part by these major
methodologic advancements. The one element of this
effort that has not optimized measurement of outcomes
nor made it easier to detect the effect of treatments is
the dichotomization of continuous measures of response,
creating responders and non-responder definitions (for
example, ACR20 responders; EULAR good responders).
Dichotomizing response sacrifices statistical power and
eliminates variability in response. Future methodologic
work will need to focus on improving multidimensional
outcome measurement without arbitrarily characterizing
some patients as responders while labeling others as
non-responders.* Correspondence: dfelson@bu.edu
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© BioMed Central Ltd.2014Prior to 1990 in rheumatology and especially in rheuma-
toid arthritis (RA), trials tested the efficacy of treatments
using outcome measures that varied from trial to trial.
One trial might assess 12 outcomes related to symptoms
and signs of disease (for example, joint counts, pain,
erythrocyte sedimentation rate, morning stiffness), while
another might include as many as 15, yet these out-
comes might be different from the ones measured in the
first trial. Because so many different outcomes were
assessed with no primary outcome, the meaning of trial
results when one or two of the outcomes showed effi-
cacy for a treatment was unclear. Further, it was not
possible to compare the efficacy of treatments across tri-
als because each trial generally used its own set of out-
come measures. In trial reports authors could report
evidence that a treatment’s efficacy was superior to pla-
cebo if 1 of 12 outcome measures showed a significant
effect of treatment, whereas in another trial report in the
same journal, authors could suggest that the same treat-
ment was not efficacious if 2 or 3 of the outcomes
showed significant efficacy over placebo. The lack of
standardization across trials and the use of multiple
comparisons made it impossible to identify which drugs
were actually efficacious and how they compared with
one another. In addition, many of the outcome mea-
sures used in these trials were not sensitive to change
and would not have shown efficacy even if the treat-
ment worked terrifically well. Further, the same out-
come measures were not always assessed using the
same techniques, so that the sensitivity to change of
one of the measures might be different in one trial
versus another.
With that background, an international group of rheu-
matologists meeting under the auspices of the American
College of Rheumatology (ACR) collected data from ran-
domized trials of second line drugs in RA and carried
out a series of analyses that examined, among trials of
known effective drugs, which of the outcome measures
being used were likely to show efficacy [1]. Among the
commonly used outcome measures that were unlikely to
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proximal interphalangeal circumference, walk time,
functional class (graded 1 through 4), hemoglobin, grip
strength and morning stiffness. Morning stiffness was
not sensitive to change because it was absent in many
patients with RA, making it impossible for them to ex-
perience an improvement when treated with an effective
drug [1]. Among the outcome measures that were found
to be most sensitive to change were the patient global
assessment, tender joint count and, in trials of second
line drugs, swollen joint count and erythrocyte sedimen-
tation rate.
Taking into account the sensitivity to change, the de-
sire to eliminate redundant measures (for example, ten-
der joint count and tender joint score) and attempting
to select outcome measures that represented the breadth
of RA manifestations, the ACR Committee chose a core
set of variables to be included in all trials (Table 1), a
recommendation that was later endorsed by the Inter-
national League Against Rheumatism and the World
Health Organization [2].
With this list of seven measures, the committee had
standardized RA outcome assessment and decreased the
number of outcome measures. However, trials still
assessed seven measures, often with all as primary out-
comes, and there needed to be a single measure that
reflected the breadth of RA activity, including both
physician-measured assessments and patient-reported
outcomes. With this in mind, an international commit-
tee again assembled and tested a variety of possible defi-
nitions of improvement. Using different thresholds and
combinations of core set measures, the committee chose
a definition that showed the greatest sensitivity to
change. Other factors considered by the committee in-
cluded ease of use, and accord with rheumatologists’ im-
pressions of improvement. The ACR definition of
improvement [3] (often called the ACR20 because itTable 1 American College of Rheumatology disease
activity measures for rheumatoid arthritis clinical trials:
Core Set
Disease activity measure
1 Tender joint count
2 Swollen joint count
3 Patient’s assessment of pain
4 Patient’s global assessment of disease activity
5 Physician’s assessment of physical function
6 Patient’s assessment of physical function
7 Acute-phase reactant value
For trial duration ≥1 year and agent being tested as a ‘DMARD’, also perform:
8 Radiography or other imaging technique
DMARD disease-modifying anti-rheumatic drug.requires at least a 20% improvement in the core set mea-
sures for a patient to reach improvement) was promul-
gated and has been widely adopted in RA trials. A little
later, the European League Against Rheumatism
(EULAR) also developed their own definition of re-
sponse [4], which broke improvement into three cat-
egories and, unlike the ACR definition, required both a
low level of disease and a certain degree of improvement
for a patient to be characterized as having good im-
provement. Subsequent work has suggested that the
ACR20 and the EULAR definition of improvement per-
form comparably [5], and many trials have included
both, choosing one of the measures as a primary out-
come and reporting the other as a secondary outcome.
Importantly, the US Food and Drug Administration also
recommended the ACR20 as a preferred outcome meas-
ure for testing the efficacy of new drugs for RA with re-
spect to signs and symptoms of disease. Since most trials
in RA are carried out by industry, this endorsement by
the Food and Drug Administration was a critical elem-
ent to the widespread dissemination and use of the
ACR20. Even now [6], the ACR20 is probably the most
widely used outcome measure in RA trials.
With the success and widespread use of the ACR20
came the desire among rheumatologists studying other
rheumatic diseases to have similar standardized defini-
tions of response and improvement. In the few years
after the ACR20 was published, similar efforts were
undertaken for juvenile RA, osteoarthritis, low back
pain, psoriatic arthritis, and spondyloarthropathies; more
recently, efforts for myositis and vasculitis have paral-
leled earlier efforts with a focus on developing a uniform
set of measures for trial outcomes and sometimes defin-
ing a threshold for improvement.
It is not surprising that the promulgation of a ration-
ally selected core set of outcome measures and its con-
solidation into one multidimensional measure of
response has occurred contemporaneously with the im-
provement of treatments in rheumatic disease. Making
uniform and efficient the measurement of response in
rheumatic disease has facilitated the comparison of new
and conventional treatments. For example, the ACR20
and variations on this measurement tool have been used
to assert that anti-tumor necrosis factor inhibitors per-
form as well or better than conventional treatments in
RA [7], an argument that would have been difficult to
make with the old chaotic scheme of multiple measure-
ments. Also, meta-analyses have convincingly demon-
strated that some new therapies for RA did not work as
well as either conventional or new biologic agents
[8-10]. These treatments shown to be less efficacious
have then lost favor in the marketplace.
Table 2 shows an enumeration of the benefits of defin-
ing response from a methods perspective. The
Table 2 Beneficial and detrimental effects of Core Set and
ACR20 on trials in rheumatoid arthritis
Beneficial effects Detrimental effects
Selected outcome measures most likely
to change with treatment
Dichotomized a continuous
measures of response
Made uniform trial outcome measures
across studies, making comparisons
possible
Decreased the number of outcomes
from >10 to 7 and then to 1 (ACR20)
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insensitive to change improved the likelihood that effect-
ive treatments would be found. The widespread agree-
ment to adopt uniformity with respect to trial outcomes
made comparisons of treatments possible and even
allowed for examination of the consistency of efficacy
across trials of the same treatment. The development of
core set measures and the ultimate definition of re-
sponse decreased the multiple comparison problems in
RA trials and other rheumatic disease trials. The con-
solidation of multiple selected outcome measures into
one composite measure also served to improve statistical
power, providing a single measure that represented mul-
tiple elements of disease activity (for example, the RA
core set has elements of patient measures, physician
measures and blood tests). Analyses of trial data showed
that, since the core set measures were all correlated with
one another, it was rare for patients to experience ex-
tremely discordant outcomes across the measures - gen-
erally, if a patient improved, most or all of the measures
improved, although often not to the same extent. The
core set has served the scientific community well but it
is likely that many of the measures for RA and for other
diseases will be refined with the development of new
patient-reported outcomes such as those produced by
the National Institutes of Health’s Patient Reported Out-
comes Measurement Information System initiative (for
example).
Unfortunately, one effect of this process has not been
beneficial (Table 2). In developing a definition of re-
sponse, the ACR Committee and other rheumatic dis-
ease study groups have used thresholds to define
response. Often clinically based, these thresholds initially
seemed like a wonderful way of communicating the ef-
fect of a new treatment, that a certain number of pa-
tients would experience improvement when treated. The
problem is that taking a continuous measure and arbi-
trarily cutting it so as to create a dichotomous response/
non-response measure, called 'responder analyses', sacri-
fices statistical power and inflates the number of patients
needed to evaluate the efficacy of treatments. Due
mostly to their loss of power, responder analyses are dis-
couraged in the clinical trials literature [11], and in arecent position paper, the Pharmaceutical Research and
Manufacturers of America (PhRMA) have advised
against use of these analyses [12]. The loss of power in
these analyses has been repeatedly shown in simulation
studies [13] and has been the subject of prominent edi-
torials in clinical journals [14]. As noted by Altman and
Royston [14], responder analyses lead to several prob-
lems. First, statistical power is reduced; they estimate
that it is equivalent to discarding one-third of the data
collected. This is especially inadvisable when only small
numbers of patients can be recruited, an especially acute
problem in some rare rheumatic diseases like myositis,
vasculitis and scleroderma. Generally speaking, the use
of a dichotomized response/non-response measure
should be discouraged in studies of these diseases and
probably in other rheumatic disease trials too. Altman
and Royston and the PhRMA position paper also note
other problems introduced by responder analysis, in-
cluding an underestimation of the degree of variation
between groups with variation subsumed within each re-
sponse group and yet made invisible when the response
is dichotomized. Individuals close to each other, but on
opposite sides of the response cut point, are character-
ized as being very different rather than similar.
With the enlarging armamentarium of effective treat-
ments in RA, the need to compare the efficacy of treat-
ments will intensify. Small differences would be
expected and use of a dichotomous measure of response
would demand very large sample sizes to compare treat-
ments. This goal could be accomplished more efficiently
with a continuous outcome measure. Further, if only
small numbers of patients are needed to test a treatment
in a subgroup of persons with RA (or among those with
other rheumatic disorders), a continuous outcome meas-
ure will facilitate the testing of treatment without de-
manding impractically large sample sizes. Given these
anticipated needs, an ACR committee once again assem-
bled and created a new outcome measure based on the
ACR20 called the ACRHybrid. With the ACRHybrid a
patient’s response is based mostly on their average per-
centage improvement in the core set measures with the
caveat that average improvement is adjusted based on
whether it satisfies the ACR20, 50 or 70. While endorsed
by the ACR [15], the ACRHybrid has yet to be used as a
primary outcome measure in any large-scale RA trial.
This measure or another continuous measure would
permit the definitive evaluation of the comparative
efficacy of RA treatments and would facilitate evaluation
of how regimens compare in terms of efficacy. The con-
tinued use of dichotomous measures to evaluate these
issues has made the evaluation of therapeutic uncertain-
ties more challenging at a time when it is increasingly
necessary to determine which of our new agents is more
efficacious.
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and can hide valuable information about treatment re-
sponse, this does not mean that clinical investigators should
avoid defining important dichotomous outcomes like the
minimally important clinical improvement or disease activ-
ity low enough to be acceptable to patients. It just means,
especially for trials of treatments of uncommon rheumatic
diseases, comparative RA trials and other similar situations,
that these dichotomous measures should not be used as
primary outcomes. Recommendations on how to define
these dichotomous outcomes can be found elsewhere [16].
Beyond RA, the continued development and use of di-
chotomous measures of response in rheumatic diseases
may be sacrificing our ability to detect whether treat-
ments are efficacious. While core set measures need to
be developed for rheumatic disease trials and these
ought to follow the process used for RA, the final step
of that process should be to identify a single multidi-
mensional outcome on a continuous scale.Conclusion
The past 20 years have witnessed huge advances not just
in the armamentarium of treatments available for RA but
in the use of valid and responsive measurement tools to
assess their effectiveness. Selecting outcome measures
sensitive to change, consolidating these into single mea-
sures and adopting standardization of measurement
across trials has facilitated the assessment of treatments.
The dichotomization of treatment response has unfortu-
nately not produced major benefits and should be jetti-
soned in favor of a primary assessment of treatment
efficacy that utilizes continuous response measures.Note: This article is part of the collection Research through the
eyes of pioneers. Other articles in this series can be found at
http://arthritis-research.com/series/pioneers.Abbreviations
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